AC Immune Seeks Partner For First Anti-Tau Vaccine To Reach The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.